Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. (SHE:301584)
China · Delayed Price · Currency is CNY 28.71
-0.40 (-1.37%)
At close: Feb 12, 2026
SHE:301584 Revenue
Shanghai C&D INNOSTIC Medical Technology Group had revenue of 9.83B CNY in the half year ending June 30, 2025. This brings the company's revenue in the last twelve months to 19.30B. In the year 2024, Shanghai C&D INNOSTIC Medical Technology Group had annual revenue of 17.92B with 16.06% growth.
Revenue (ttm)
19.30B
Revenue Growth
+16.06%
P/S Ratio
0.62
Revenue / Employee
9.19M
Employees
2,099
Market Cap
11.96B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 17.92B | 2.48B | 16.06% |
| Dec 31, 2023 | 15.44B | 3.56B | 29.97% |
| Dec 31, 2022 | 11.88B | 1.86B | 18.54% |
| Dec 31, 2021 | 10.02B | 1.48B | 17.35% |
| Dec 31, 2020 | 8.54B | 1.60B | 23.08% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| COFCO Biotechnology | 18.19B |
| Jiangsu Shagang | 13.89B |
| Yinbang Clad Material Co.,Ltd | 6.07B |
| Shanghai Liangxin Electrical Co.,LTD. | 4.62B |
| Zhejiang Jingu Company | 3.56B |
| Shenzhen Colibri Technologies | 2.45B |
| Guangdong Xianglu Tungsten | 2.06B |
| Wuhan Tianyuan Group | 1.92B |